- Home
- JFU vs PSTV Comparison
JFU vs PSTV Comparison
Compare JFU & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | PSTV |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 27.5M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JFU | PSTV |
|---|---|---|
| Price | $2.30 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 2.1K | ★ 196.3K |
| Earning Date | 12-09-2022 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.51 | $0.13 |
| 52 Week High | $9.48 | $8.00 |
Technical Indicators
Market Signals| Indicator | JFU | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 36.90 |
| Support Level | N/A | $3.70 |
| Resistance Level | $2.88 | $4.51 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 16.05 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).